NCT01607346View on ClinicalTrials.gov

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

PHASE4TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 27, 2013

Primary Completion Date

November 16, 2016

Study Completion Date

November 16, 2016

Conditions
Epilepsy
Interventions
DRUG

ezogabine/retigabine

Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses

Trial Locations (7)

20817

GSK Investigational Site, Bethesda

35033

GSK Investigational Site, Rennes

43210

GSK Investigational Site, Columbus

53715

GSK Investigational Site, Madison

67091

GSK Investigational Site, Strasbourg

75251

GSK Investigational Site, Dallas

02-957

GSK Investigational Site, Warsaw

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01607346 - An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures | Biotech Hunter | Biotech Hunter